CV6 Therapeutics Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168
August 15, 2024 04:00 ET
|
CV6 Therapeutics
– Study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumor activity for CV6-168 in the treatment of multiple solid cancers, including colon, gastric, breast, ovarian,...
CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial
December 14, 2023 03:00 ET
|
CV6 Therapeutics
BELFAST, United Kingdom, Dec. 14, 2023 (GLOBE NEWSWIRE) -- CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer...